Tenet Healthcare (THC) Stock Rockets 23% on Stellar Q2 Earnings Performance

Key Highlights

Table of Contents

Tenet Healthcare shares skyrocketed 23% following a blockbuster Q2 report showing adjusted EPS of $6.12 versus the $4.26 consensus forecast
The company boosted its annual EPS forecast to $20.30–$21.69 from the previous $16.38–$18.68 range
HCA Healthcare climbed a modest 3.7% after confirming previously disclosed Q2 figures
HCA reduced its annual EPS projection to $28.70–$30.50 from $29.10–$31.50
Investment firm Barclays increased its Tenet target price to $271 from $240 while keeping its Overweight stance

Tenet Healthcare (THC) shares exploded 23% higher during Friday’s trading session, marking what could be the stock’s most significant one-day rally since February. The dramatic move followed the company’s release of second-quarter earnings that significantly exceeded Wall Street projections while substantially upgrading its annual forecast.

Tenet Healthcare Corporation, THC

The healthcare provider delivered second-quarter adjusted profits of $6.12 per share, substantially surpassing the analyst consensus of $4.26. Total operating revenue climbed 6.8% year-over-year to reach $5.63 billion, exceeding the anticipated $5.43 billion.

Management substantially increased its annual adjusted EPS forecast to between $20.30 and $21.69, representing a significant jump from the earlier projection of $16.38 to $18.68. The company’s full-year net operating revenue guidance was similarly elevated to $21.9 billion–$22.5 billion from the prior $21.5 billion–$22.3 billion range.

$THC Q2 2026 earnings: Massive Margin Expansion and Buybacks Eclipse Volume Softness

Tenet Healthcare delivered a dramatic Q2 beat, fueled by exceptional hospital margin expansion and pricing power in its ambulatory segment. While net operating revenues grew a respectable 6.8%… pic.twitter.com/pxCFX3irFc

— Finsee (@Finsee_main) July 24, 2026

The midpoint of these revised forecasts substantially exceeds analyst projections, which had been calling for earnings of $17.94 per share and revenue of $21.97 billion.

HCA Healthcare Presents Contrasting Results

HCA Healthcare released its quarterly results on the same day, though investor response proved considerably more subdued. HCA shares advanced 3.7%, a fraction of Tenet’s explosive move.

The divergence largely stems from earlier disclosure. HCA had already announced its second-quarter performance on July 14, meaning Friday’s formal release contained minimal new information for market participants.

HCA reported second-quarter adjusted earnings of $7.59 per share, marginally beating the $7.56 estimate. Revenue increased 9% to $20.23 billion, surpassing the $19.76 billion consensus projection.

Yet a substantial $400 million net gain from Medicaid supplemental payments significantly boosted these figures. When accounting for this benefit, the underlying performance appeared less robust.

HCA highlighted an increase in uninsured patient volumes, partially attributed to expanded loss of exchange-based insurance coverage throughout the quarter. Management estimated this trend reduced pre-tax income by approximately $400 million.

HCA Reduces Annual Projections

HCA trimmed its full-year EPS forecast to $28.70–$30.50 from the earlier $29.10–$31.50 range. The company also narrowed its revenue guidance to $77 billion–$79.5 billion versus the previous $76.5 billion–$80 billion projection.

The S&P 500 declined modestly on Friday, making Tenet’s 23% surge even more remarkable against the wider market environment.

Barclays raised its price objective on Tenet to $271 from $240 while maintaining its Overweight recommendation. The firm noted that Tenet’s second-quarter results “stand out and reinforce the case for a premium valuation,” especially considering guidance reductions from competing hospital operators.

Tenet’s extensive ambulatory surgery center platform has emerged as a crucial competitive advantage. While both organizations operate hospitals and outpatient centers nationwide, Tenet maintains greater exposure to its surgery center operations, which have consistently delivered strong margin performance.

Barclays’ revised $271 price objective suggests additional upside potential even after Friday’s substantial post-earnings appreciation.

✨ Limited Time Offer